Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 2.707B
March 31, 2026 2.706B
December 31, 2025 2.935B
September 30, 2025 2.706B
June 30, 2025 2.705B
March 31, 2025 2.705B
December 31, 2024 2.908B
September 30, 2024 2.704B
June 30, 2024 2.704B
March 31, 2024 2.703B
December 31, 2023 2.703B
September 30, 2023 2.703B
June 30, 2023 2.702B
March 31, 2023 2.702B
December 31, 2022 2.701B
September 30, 2022 2.701B
June 30, 2022 2.701B
March 31, 2022 2.700B
December 31, 2021 2.700B
September 30, 2021 2.699B
June 30, 2021 2.698B
March 31, 2021 2.697B
December 31, 2020 2.696B
September 30, 2020 2.695B
June 30, 2020 715.90M
Date Value
March 31, 2020 715.20M
December 31, 2019 713.90M
September 30, 2019 712.70M
June 30, 2019 711.30M
March 31, 2019 709.90M
December 31, 2018 708.50M
September 30, 2018 707.20M
June 30, 2018 705.90M
March 31, 2018 704.64M
December 31, 2017 703.45M
September 30, 2017 702.32M
June 30, 2017 701.17M
March 31, 2017 707.61M
December 31, 2016 478.84M
September 30, 2016 382.23M
June 30, 2016 361.52M
March 31, 2016 362.23M
December 31, 2015 362.92M
September 30, 2015 394.87M
June 30, 2015 388.05M
March 31, 2015 472.48M
December 31, 2014 457.71M
September 30, 2014 565.31M
June 30, 2014 517.85M
March 31, 2014 531.11M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 2.942B
AbbVie, Inc. 70.82B
Gilead Sciences, Inc. 26.25B
Amgen, Inc. 57.30B
Biogen, Inc. 8.355B